CoChat

A 3D bioengineered human liver for the study of acute and chronic drug-induced hepatotoxicity and fibrosis

Open access
Ferret-Miñana, Ainhoa, Alcaraz, Estefanía, Horrillo, Raquel, Ramón-Azcón, Javier, De Chiara, Francesco · 2026 · Frontiers in Bioengineering and Biotechnology

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index; 16 of the 31 sources its claims cite were checked for support.

Abstract

The liver is frequently exposed to acute and chronic insults that disrupt its function, leading to inflammation, fibrosis, and serious conditions like cirrhosis and hepatocellular carcinoma. Fibrosis, driven by the activation of hepatic stellate cells is a key feature of chronic liver damage. Traditional 2D liver models face limitations in maintaining liver functions and accurately replicating chronic conditions like fibrosis. In response to these needs, 3D models have emerged as more physiologically relevant platforms for studying liver disease and drug testing. However, most existing 3D models still lack chronic injury features or immune elements. In this study, we developed a 3D human-liver model to investigate both acute and chronic drug-induced liver injury. The model consists of encapsulated human hepatocytes (HepaRG) and hepatic stellate cells (LX-2) within a gelatin methacryloyl (GelMA) and carboxymethyl cellulose methacrylate matrix. Over a 30-day culture period, the 3D liver constructs maintained physiologically relevant functions, including albumin secretion and cytochrome P450 activity, which are lost rapidly in conventional 2D models. The model enabled reliable simulation of low-level, long-term, and high-dose, short-term damage by administering lipopolysaccharide and Paracetamol. Chronic liver injury was characterized by progressive fibrosis, elevated expression of COL1A1, and persistent hyperammonemia. In contrast, acute models showed significant but transient injury. Moreover, dexamethasone treatment successfully reversed fibrotic markers and restored hepatocyte functionality, indicating the model's predictive power for evaluating potential therapies. Incorporating human monocytes (THP-1) allowed investigation of the immune response and macrophage activation, which are critical contributors to liver disease pathogenesis. Overall, this 3D liver model offers a physiologically relevant and versatile platform for studying complex multi-cellular interactions under acute and chronic injury. It has broad implications for drug safety screening, disease modeling, and personalized therapy. The tri-culture design extends the model's capacity to elucidate immune-driven hepatic pathology.

Overview

CoChat Summary

TL;DR

This paper develops a 3D human liver tissue model (HepaRG hepatocytes + LX-2 stellate cells, later with THP-1 monocytes) that stays functional for 30 days and reproduces both chronic and acute drug-induced liver injury. It shows progressive fibrosis, metabolic dysfunction, and inflammatory activation under LPS + paracetamol challenge, and dexamethasone reverses many of these injury markers.

Key findings

  • The 3D liver constructs maintained viability and liver function for up to 30 days: MTS and Live/Dead assays showed no significant viability decline, CYP3A4 activity increased at days 10, 20, and 30 vs day 0 (p < 0.0001), and albumin, CPS1, and OTC expression increased over time.
  • Under chronic injury conditions (LPS 10 ng/mL + paracetamol 0.75 mM), the model showed progressive fibrosis and impaired function: COL1A1 increased over days 10–30, PIIINP and PINP were higher from day 10 to day 30 (p < 0.01), IL-6 and MCP-1 increased, and chronic-damage samples had 528 downregulated genes in the Untreated Day 0 vs Chronic Day 30 comparison.
  • Chronic damage also reduced metabolic capacity: CYP3A4 activity was significantly lower at all time points, live/dead assays showed an approximately 50% decline in cell viability starting at day 10, and nuclear area increased significantly from day 10 onward (p < 0.0001).
  • Acute injury (LPS 100 ng/mL + paracetamol 2.5 mM) caused rapid dysfunction by day 3: Live/Dead and MTS both dropped significantly, CYP3A4 activity fell (p < 0.0001), albumin and CPS1 mRNA decreased, COL1A1 increased (p < 0.05), and ammonia levels rose (p < 0.01).

Methods

  • Human 3D liver tissues were fabricated by encapsulating HepaRG hepatocytes and LX-2 hepatic stellate cells in a GelMA-CMCMA hydrogel using PDMS ring molds; the standard ratio was 2:1 (HepaRG:LX-2), with cultures maintained in serum-free differentiation medium for up to 30 days.
  • Chronic injury was induced with LPS 10 ng/mL + paracetamol 0.75 mM for 30 days; acute injury with LPS 100 ng/mL + paracetamol 2.5 mM for 3 days; dexamethasone 100 nM was used to test rescue in both models.
  • Analyses included Live/Dead staining, MTS assay, CYP3A4 activity assay, immunofluorescence/confocal imaging, qPCR, RNA-seq with DESeq2 and GSEA, ammonia/PINP/PIIINP measurements, and transwell co-culture with THP-1 monocytes plus NF-κB luciferase and cytokine assays.

Limitations

  • The paper states that the model does not fully represent other non-parenchymal liver cells, such as endothelial cells and Kupffer cells, which may limit how completely it captures liver pathophysiology.
  • It also states that patient-specific genetic and etiological factors are not accounted for because standardized cell lines are used.
  • Evident from the text: the model relies on transformed/immortalized cell lines and transwell co-culture rather than fully primary human liver tissue, which may constrain translational generalizability.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3389/fbioe.2026.1798323

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

FIGURE 1 Fabrication and characterization of the 3D liver model cultured for 30 days. (A,B) Schematic representation of the fabrication process of the 3D liver model. Hepatocytes (HepaRG) and hepatic stellate cells (LX-2) are encapsulated within a GelMA-CMCMA hydrogel matrix. Cells were encapsulated on Day −2, transferred to serum-free medium (SFM) on Day −1, and challenged with treatments starting at Day 0. Samples were collected at Days 0, 10, 20, and 30 for analysis. (C) Gene Set Enrichment Analysis (GSEA) of biological processes related to hepatocyte differentiation (green), cell death (blue), and hepatocyte maturation (red) over time. The bubble plots show normalized enrichment scores (NES) and adjusted p-values across Days 10, 20, and 30 (left to right). (D) Radar chart showing the log2 fold change of selected hepatocyte-related genes grouped by interactors (string database) of Albumin, CYP3A4, HNF1a, HNF4a. (E) Bar graphs of gene expression changes (log2 fold change) for selected genes at Days 10, 20, and 30. Red bars represent upregulated genes, while blue bars represent downregulated genes. (F) Live/Dead and MTS assays. The Live/Dead assay shows consistent cell viability across time points, while the MTS assay reveals stable metabolic activity. (G) mRNA expression levels measured by qPCR of hepatocyte markers (Albumin, CPS1, OTC) and the fibrosis marker Col1α1 across time points. (H) Immunofluorescence imaging of albumin (green), nuclei (blue), and merged images over 30 days. The statistical significance is so represented: *= 0.05; **= 0.01; ***= 0.001; ****= 0.0001 in at least three independent experiments. These results validate the establishment and characterization of the 3D liver model, providing insights into hepatocyte function, gene expression dynamics, and metabolic responses over time. The model demonstrates its suitability for studying chronic liver injury and associated cellular processes.
FIGURE 1 Fabrication and characterization of the 3D liver model cultured for 30 days. (A,B) Schematic representation of the fabrication process of the 3D liver model. Hepatocytes (HepaRG) and hepatic stellate cells (LX-2) are encapsulated within a GelMA-CMCMA hydrogel matrix. Cells were encapsulated on Day −2, transferred to serum-free medium (SFM) on Day −1, and challenged with treatments starting at Day 0. Samples were collected at Days 0, 10, 20, and 30 for analysis. (C) Gene Set Enrichment Analysis (GSEA) of biological processes related to hepatocyte differentiation (green), cell death (blue), and hepatocyte maturation (red) over time. The bubble plots show normalized enrichment scores (NES) and adjusted p-values across Days 10, 20, and 30 (left to right). (D) Radar chart showing the log2 fold change of selected hepatocyte-related genes grouped by interactors (string database) of Albumin, CYP3A4, HNF1a, HNF4a. (E) Bar graphs of gene expression changes (log2 fold change) for selected genes at Days 10, 20, and 30. Red bars represent upregulated genes, while blue bars represent downregulated genes. (F) Live/Dead and MTS assays. The Live/Dead assay shows consistent cell viability across time points, while the MTS assay reveals stable metabolic activity. (G) mRNA expression levels measured by qPCR of hepatocyte markers (Albumin, CPS1, OTC) and the fibrosis marker Col1α1 across time points. (H) Immunofluorescence imaging of albumin (green), nuclei (blue), and merged images over 30 days. The statistical significance is so represented: *= 0.05; **= 0.01; ***= 0.001; ****= 0.0001 in at least three independent experiments. These results validate the establishment and characterization of the 3D liver model, providing insights into hepatocyte function, gene expression dynamics, and metabolic responses over time. The model demonstrates its suitability for studying chronic liver injury and associated cellular processes.CC BY · PubMed Central
FIGURE 2 In vitro three-dimensional model of chronic liver damage using human hepatocytes and hepatic stellate cells. (A) Experimental timeline. Encapsulation of hepatocytes and hepatic stellate cells was performed on Day −2, followed by a transition to serum-free medium (SFM) on Day −1. Chronic liver damage was induced on Day 0 using LPS (10 ng/mL) and Paracetamol (0.75 mM). Samples were collected at Days 10, 20, and 30 for analysis. (B) Principal component analysis (PCA) of transcriptomic data based on the top 80% most variable genes (n = 5 per group). (C) Heatmap displaying the top 10% most differentially expressed genes across all samples. (D) Volcano plots comparing chronic-damage samples with their time-matched untreated controls (Day 10: top-left; Day 20: top-right; Day 30: bottom). Genes with log2 fold change ≥1 and adjusted p ≤ 0.001 are coloured red (upregulated); those with log2 fold change ≤−1 and adjusted p ≤ 0.001 are coloured blue (downregulated). (E) Heatmap of selected biological processes, including fibrosis, hepatic stellate cell activation, hepatocyte death, urea cycle, and hepatocyte differentiation. (F,G) mRNA expression levels of hepatocyte-specific markers (Albumin, CPS1, OTC) and ammonia levels in the medium. (H) CYP3A4 activity. (I) mRNA expression of COL1A1 (fibrotic marker). (J) Enzymatic assays for fibrosis-related markers (PIIINP and PINP). The statistical significance is denoted as follows: *= 0.05; **= 0.01; ***= 0.001; ****= 0.0001. These data highlight the metabolic, transcriptional, and fibrotic changes induced by chronic liver damage in the 3D liver model, demonstrating its utility in studying the mechanisms of liver disease.
FIGURE 2 In vitro three-dimensional model of chronic liver damage using human hepatocytes and hepatic stellate cells. (A) Experimental timeline. Encapsulation of hepatocytes and hepatic stellate cells was performed on Day −2, followed by a transition to serum-free medium (SFM) on Day −1. Chronic liver damage was induced on Day 0 using LPS (10 ng/mL) and Paracetamol (0.75 mM). Samples were collected at Days 10, 20, and 30 for analysis. (B) Principal component analysis (PCA) of transcriptomic data based on the top 80% most variable genes (n = 5 per group). (C) Heatmap displaying the top 10% most differentially expressed genes across all samples. (D) Volcano plots comparing chronic-damage samples with their time-matched untreated controls (Day 10: top-left; Day 20: top-right; Day 30: bottom). Genes with log2 fold change ≥1 and adjusted p ≤ 0.001 are coloured red (upregulated); those with log2 fold change ≤−1 and adjusted p ≤ 0.001 are coloured blue (downregulated). (E) Heatmap of selected biological processes, including fibrosis, hepatic stellate cell activation, hepatocyte death, urea cycle, and hepatocyte differentiation. (F,G) mRNA expression levels of hepatocyte-specific markers (Albumin, CPS1, OTC) and ammonia levels in the medium. (H) CYP3A4 activity. (I) mRNA expression of COL1A1 (fibrotic marker). (J) Enzymatic assays for fibrosis-related markers (PIIINP and PINP). The statistical significance is denoted as follows: *= 0.05; **= 0.01; ***= 0.001; ****= 0.0001. These data highlight the metabolic, transcriptional, and fibrotic changes induced by chronic liver damage in the 3D liver model, demonstrating its utility in studying the mechanisms of liver disease.CC BY · PubMed Central
FIGURE 3 Morphological, transcriptional, and cellular responses in the chronic damage model. (A) Immunofluorescence staining comparing untreated and chronic damage conditions across Days 10, 20, and 30. Top row: Albumin (green), Collagen I (red), and nuclei (blue). Scale bar = 100 µm. Middle row: Albumin (green), vimentin (red), and nuclei (blue). Scale bar = 200 µm. Bottom row: Lipid droplets (orange) and nuclei (blue). Scale bar = 100 µm. (B) Box plots showing log2 fold changes in genes associated with fatty acid biosynthesis, sphingolipid metabolism, fatty acid degradation, and glycolysis/pyruvate metabolism over Days 10, 20, and 30. (C) Live/Dead assay. (D) Nuclear morphology at Day 10 in untreated and chronic damage models. Chronic damage results in nuclear enlargement (arrow) compared to untreated samples. (E) Quantification of nuclear area reveals significantly larger nuclei in the chronic damage model. The statistical significance is represented as follows: ns = not significant; ****= 0.0001. These results demonstrate the progressive impact of chronic damage on hepatocyte function, lipid metabolism, fibrosis, and nuclear morphology in the 3D liver model, highlighting the model’s utility for studying chronic liver injury and related metabolic dysfunctions.
FIGURE 3 Morphological, transcriptional, and cellular responses in the chronic damage model. (A) Immunofluorescence staining comparing untreated and chronic damage conditions across Days 10, 20, and 30. Top row: Albumin (green), Collagen I (red), and nuclei (blue). Scale bar = 100 µm. Middle row: Albumin (green), vimentin (red), and nuclei (blue). Scale bar = 200 µm. Bottom row: Lipid droplets (orange) and nuclei (blue). Scale bar = 100 µm. (B) Box plots showing log2 fold changes in genes associated with fatty acid biosynthesis, sphingolipid metabolism, fatty acid degradation, and glycolysis/pyruvate metabolism over Days 10, 20, and 30. (C) Live/Dead assay. (D) Nuclear morphology at Day 10 in untreated and chronic damage models. Chronic damage results in nuclear enlargement (arrow) compared to untreated samples. (E) Quantification of nuclear area reveals significantly larger nuclei in the chronic damage model. The statistical significance is represented as follows: ns = not significant; ****= 0.0001. These results demonstrate the progressive impact of chronic damage on hepatocyte function, lipid metabolism, fibrosis, and nuclear morphology in the 3D liver model, highlighting the model’s utility for studying chronic liver injury and related metabolic dysfunctions.CC BY · PubMed Central
FIGURE 4 Functional, transcriptional and morphological changes in the acute damage model. (A) Experimental timeline. Encapsulation of 3D liver tissues was performed on Day −2, followed by a switch to serum-free medium (SFM) on Day −1. Acute liver damage was induced on Day 0 using LPS (100 ng/mL) and Paracetamol (2.5 mM). Samples were analyzed on Day 3. (B) Quantification of cellular viability, metabolic activity, and CYP3A4 activity. (C) Hepatocyte-specific and fibrotic markers gene expression. mRNA expression of hepatocyte markers Albumin, CPS1, and COL1A1 measured by qPCR. (D) Ammonia levels in the medium. (E) Nuclear area. (F) Immunofluorescence staining for albumin and OTC in green, fibrosis markers such as vimentin, α-SMA, and Collagen I in red, and nuclei in blue. (G) Lipid accumulation. Lipid staining (orange) and nuclear staining (blue). The statistical significance is denoted as follows: *= 0.05; **= 0.01; ***= 0.001; ****= 0.0001. These findings highlight the severe impact of acute liver damage on hepatocyte functionality, metabolic activity, and structural integrity, as well as the activation of fibrogenic responses and dysregulation of lipid metabolism. The 3D liver model effectively recapitulates key aspects of acute liver injury.
FIGURE 4 Functional, transcriptional and morphological changes in the acute damage model. (A) Experimental timeline. Encapsulation of 3D liver tissues was performed on Day −2, followed by a switch to serum-free medium (SFM) on Day −1. Acute liver damage was induced on Day 0 using LPS (100 ng/mL) and Paracetamol (2.5 mM). Samples were analyzed on Day 3. (B) Quantification of cellular viability, metabolic activity, and CYP3A4 activity. (C) Hepatocyte-specific and fibrotic markers gene expression. mRNA expression of hepatocyte markers Albumin, CPS1, and COL1A1 measured by qPCR. (D) Ammonia levels in the medium. (E) Nuclear area. (F) Immunofluorescence staining for albumin and OTC in green, fibrosis markers such as vimentin, α-SMA, and Collagen I in red, and nuclei in blue. (G) Lipid accumulation. Lipid staining (orange) and nuclear staining (blue). The statistical significance is denoted as follows: *= 0.05; **= 0.01; ***= 0.001; ****= 0.0001. These findings highlight the severe impact of acute liver damage on hepatocyte functionality, metabolic activity, and structural integrity, as well as the activation of fibrogenic responses and dysregulation of lipid metabolism. The 3D liver model effectively recapitulates key aspects of acute liver injury.CC BY · PubMed Central
FIGURE 5 Effects of dexamethasone treatment on chronic and acute liver damage in the 3D liver model. (A,B) Experimental timelines for chronic (A) and acute (B) liver damage models. Encapsulation was performed on Day −2, followed by a switch to serum-free medium (SFM) on Day −1. For the chronic model, liver damage was induced with LPS (10 ng/mL) and Paracetamol (0.75 mM) on Day 0, and dexamethasone treatment (100 nM) began on Day 2. For the acute model, liver damage was induced with higher concentrations of LPS (100 ng/mL) and Paracetamol (2.5 mM) on Day 0, and dexamethasone was applied on Day 1. (C,E) mRNA expression of hepatocyte-specific markers (Albumin, CPS1) and the fibrotic marker Col1α1 in the chronic and acute damage model measured by qPCR. (D–F) Ammonia levels in chronic and acute damage models. (G,H) Immunofluorescence staining for Albumin (green), vimentin (red), and nuclei (blue) in chronic and acute models. The statistical significance is denoted as follows: *= 0.05; **= 0.01; ***= 0.001; ****= 0.0001. These results demonstrate the protective and anti-fibrotic effects of dexamethasone in both chronic and acute liver damage models, highlighting its ability to restore hepatocyte function, reduce fibrosis, and improve metabolic activity in the 3D liver model.
FIGURE 5 Effects of dexamethasone treatment on chronic and acute liver damage in the 3D liver model. (A,B) Experimental timelines for chronic (A) and acute (B) liver damage models. Encapsulation was performed on Day −2, followed by a switch to serum-free medium (SFM) on Day −1. For the chronic model, liver damage was induced with LPS (10 ng/mL) and Paracetamol (0.75 mM) on Day 0, and dexamethasone treatment (100 nM) began on Day 2. For the acute model, liver damage was induced with higher concentrations of LPS (100 ng/mL) and Paracetamol (2.5 mM) on Day 0, and dexamethasone was applied on Day 1. (C,E) mRNA expression of hepatocyte-specific markers (Albumin, CPS1) and the fibrotic marker Col1α1 in the chronic and acute damage model measured by qPCR. (D–F) Ammonia levels in chronic and acute damage models. (G,H) Immunofluorescence staining for Albumin (green), vimentin (red), and nuclei (blue) in chronic and acute models. The statistical significance is denoted as follows: *= 0.05; **= 0.01; ***= 0.001; ****= 0.0001. These results demonstrate the protective and anti-fibrotic effects of dexamethasone in both chronic and acute liver damage models, highlighting its ability to restore hepatocyte function, reduce fibrosis, and improve metabolic activity in the 3D liver model.CC BY · PubMed Central
FIGURE 6 Inflammatory response in the chronic and acute damage models co-cultured with THP-1 NF-κB-Luc2 cells. (A) Schematic representation of healthy and acute/chronic liver damage models in co-culture with THP-1 NF-κB-Luc2 reporter cells. (B,C) Experimental timelines. In the chronic model (B), LPS (10 ng/mL) and Paracetamol (0.75 mM) were added on Day 0, followed by co-culture with THP-1 NF-κB-Luc2 reporter cells starting on Day −1 and continuing through Days 8, 18, and 28. In the acute model (C), higher concentrations of LPS (100 ng/mL) and Paracetamol (2.5 mM) were applied on Day 0, and THP-1 NF-κB-Luc2 reporter cells co-culture was initiated on Day 2 and analyzed on Day 3. (D,F) Luciferase assay in the chronic and acute models. (E,G) Levels of pro-inflammatory cytokines (IL-6, IL-1β, and TNFα) in the chronic, up to 30 days, and acute models, up to 3 days, were measured by Luminex assay in the medium. These results demonstrate the activation of the NF-κB pathway and associated inflammatory cytokines in both chronic and acute damage models. The statistical significance is denoted as follows: *= 0.05; **= 0.01; ***= 0.001; ****= 0.0001. The chronic model exhibits sustained inflammation over time, while the acute model shows a rapid and intense inflammatory response. This highlights the utility of the 3D liver model in studying inflammatory signaling in liver injury.
FIGURE 6 Inflammatory response in the chronic and acute damage models co-cultured with THP-1 NF-κB-Luc2 cells. (A) Schematic representation of healthy and acute/chronic liver damage models in co-culture with THP-1 NF-κB-Luc2 reporter cells. (B,C) Experimental timelines. In the chronic model (B), LPS (10 ng/mL) and Paracetamol (0.75 mM) were added on Day 0, followed by co-culture with THP-1 NF-κB-Luc2 reporter cells starting on Day −1 and continuing through Days 8, 18, and 28. In the acute model (C), higher concentrations of LPS (100 ng/mL) and Paracetamol (2.5 mM) were applied on Day 0, and THP-1 NF-κB-Luc2 reporter cells co-culture was initiated on Day 2 and analyzed on Day 3. (D,F) Luciferase assay in the chronic and acute models. (E,G) Levels of pro-inflammatory cytokines (IL-6, IL-1β, and TNFα) in the chronic, up to 30 days, and acute models, up to 3 days, were measured by Luminex assay in the medium. These results demonstrate the activation of the NF-κB pathway and associated inflammatory cytokines in both chronic and acute damage models. The statistical significance is denoted as follows: *= 0.05; **= 0.01; ***= 0.001; ****= 0.0001. The chronic model exhibits sustained inflammation over time, while the acute model shows a rapid and intense inflammatory response. This highlights the utility of the 3D liver model in studying inflammatory signaling in liver injury.CC BY · PubMed Central

Verification

Claims the paper makes

9 Valid · 4 Not valid · 8 Not checked · 185 Own results and interpretations

116 more claims

Create a free account to see all 206 claims and to verify the 1 reference still open.

See all claims — free account
  • It may state two separate claims as one. 75
  • The quote only partly states this claim. 1
  • Probably not a substantial claim. 10

Create a free account to see these claims.

Citations

Cites

Show all 33 references

Metadata

Authors
Ferret-Miñana, A., Alcaraz, E., Horrillo, R., Ramón-Azcón, J., & De Chiara, F.
Affiliations
  • Institute for Bioengineering of Catalonia (ES)
  • Grifols (Germany) (DE)
  • Biosensors for Bioengineering Group, Institute for Bioengineering of Catalonia (IBEC)
Venue
Frontiers in Bioengineering and Biotechnology
Published
2026-05-11
Volume
14
Pages
1798323-1798323
ISSN
2296-4185 (ISSN-L)
OpenAlex
W7160761852
Cited by
0
References
32
FWCI
0.00
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Bioengineering and Biotechnology (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Grifols
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
  • Health Sciences › Medicine › Surgery › Tissue Engineering and Regenerative Medicine
Keywords
3D liver model, drug-induced liver injury, liver fibrosis, hepatic stellate cells, gelatin methacryloyl, lipopolysaccharide, paracetamol, dexamethasone, hyperammonemia, COL1A1, THP-1 cells, macrophage activation, drug safety testing, hepatocyte function

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A 3D bioengineered human liver for the study of acute and chronic drug-induced hepatotoxicity and fibrosis. https://app.cochat.ai/papers/10.3389/fbioe.2026.1798323
The paper
Ferret-Miñana, A., Alcaraz, E., Horrillo, R., Ramón-Azcón, J., & De Chiara, F. (2026). A 3D bioengineered human liver for the study of acute and chronic drug-induced hepatotoxicity and fibrosis. Frontiers in Bioengineering and Biotechnology. https://doi.org/10.3389/fbioe.2026.1798323

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.